Humana Inc. (NYSE:HUM) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC lifted its position in shares of Humana Inc. (NYSE:HUM) by 1.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 96,375 shares of the insurance provider’s stock after acquiring an additional 1,023 shares during the period. Natixis Advisors LLC’s holdings in Humana were worth $30,526,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. raised its stake in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Creative Financial Designs Inc. ADV raised its stake in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in shares of Humana during the 3rd quarter worth $29,000. Hantz Financial Services Inc. acquired a new position in shares of Humana during the 2nd quarter worth $35,000. Finally, Family Firm Inc. acquired a new position in shares of Humana during the 2nd quarter worth $37,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. TD Cowen boosted their target price on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Oppenheimer cut their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. KeyCorp started coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, Stephens reissued an “equal weight” rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, October 9th. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $315.86.

Humana Stock Down 2.6 %

Shares of NYSE:HUM opened at $275.67 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The stock has a market capitalization of $33.19 billion, a P/E ratio of 24.42, a PEG ratio of 2.17 and a beta of 0.52. The stock has a 50-day simple moving average of $281.36 and a 200-day simple moving average of $331.94.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts forecast that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.